HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Haleon Surprises Analysts With Stand-Out Cold & Flu Showing In Q4

Executive Summary

In describing Haleon’s Q4 showing as a “strong finish to the year,” Bernstein’s Bruno Monteyne pointed to “remarkable strength in respiratory health,” with the category resoundingly beating analysts’ consensus estimates of a 2.5% decline.

You may also be interested in...

Reckitt Not Worried By Q4 Stumble At 'Jewel' OTC Business

As it felt the effects of a weaker cold & flu season, Reckitt insisted its subdued Q4 showing is not an indicator of how its Health business will perform in 2024. The unit is expected to deliver mid single-digit growth, as it did last year.

Kenvue Prioritizes Growing 15 Brands In Pivot To Recovering Marketplace Prominence

Kenvue’s plans to drive sales include re-introducing brands to consumers and making “priority” of 15 brands, most in self care. “Overall, the execution of our recovery plan in the fourth quarter fell short of expectations,” says CEO Thibaut Mongon.

Sanofi Awaiting Key Meeting With FDA To Recommence Cialis Switch

Sanofi is waiting to hear from FDA whether it has done enough to recommence its Cialis actual-use trial, which has been on hold for almost two years. The France-based firm gave an update on the Cialis switch program as it reported higher Consumer Healthcare sales in Q4.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts